Page last updated: 2024-11-06

secnidazole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Secnidazole is a nitroimidazole derivative with antiprotozoal activity. It is a prodrug that is metabolized in the liver to its active form, which has a broad spectrum of activity against anaerobic bacteria and protozoa. Secnidazole is primarily used to treat infections caused by susceptible organisms, including Giardia lamblia, Trichomonas vaginalis, and Entamoeba histolytica. Its mechanism of action involves inhibiting the synthesis of DNA in these organisms. Secnidazole is also effective against some anaerobic bacteria, such as Bacteroides fragilis, Clostridium difficile, and Prevotella spp. It is generally well-tolerated but can cause side effects such as nausea, vomiting, and diarrhea. The synthesis of secnidazole involves a multi-step process that starts with the reaction of 2-nitroimidazole with 1-chloro-2-propanol to form the key intermediate, followed by further functionalization with various reagents. Secnidazole is studied extensively for its potential applications in the treatment of various infections, including those caused by drug-resistant strains of bacteria and protozoa. It is also being investigated for its potential use in cancer therapy. Its importance lies in its ability to target organisms that are resistant to other antibiotics, making it a valuable therapeutic agent for treating a range of infectious diseases.'

Cross-References

ID SourceID
PubMed CID71815
CHEMBL ID498847
CHEBI ID140628
CHEBI ID94433
SCHEMBL ID363924
MeSH IDM0066920

Synonyms (134)

Synonym
HMS3393C20
AB00456738-15
BRD-A70083328-001-02-9
1-(2-methyl-5-nitro-imidazol-1-yl)-propan-2-ol
secnidazolum [inn-latin]
secnidazole ,
smr000149359
MLS000559043 ,
pm-185184
rp-14539
flagentyl
BSPBIO_003556
D07353
solosec (tn)
secnidazole (usan/inn)
secnidal (tn)
3366-95-8
MLS000759496
NCGC00095158-02
NCGC00095158-01
pm 185184
imidazole-1-ethanol, alpha,2-dimethyl-5-nitro-
alpha,2-dimethyl-5-nitroimidazole-1-ethanol
1-(2-methyl-5-nitro-1-imidazolyl)-2-propanol
einecs 222-134-0
rp 14539
1-(2-hydroxypropyl)-2-methyl-5-nitroimidazol
secnidazol [inn-spanish]
KBIO3_002874
SPECTRUM3_001956
SPBIO_000125
SPECTRUM2_000033
SPECTRUM1505304
MLS001201813
NCGC00095158-03
secnidazol
CHEBI:140628 ,
secnidazolum
1-(2-methyl-5-nitro-1h-imidazol-1-yl)propan-2-ol
AC-12065
HMS2051C20
HMS2090N15
1-(2-methyl-5-nitroimidazol-1-yl)propan-2-ol
HMS1922B12
secnidal
sym-1219
ornidazole metabolite m4
CHEMBL498847
nsc-759812
secnidazole anhydrous
1-(2-methyl-5-nitro-imidazol-1-yl)propan-2-ol;secnidazole
A821901
BBL010784
nsc759812
MLS001424126
pharmakon1600-01505304
tox21_111457
dtxsid3045934 ,
dtxcid1025934
cas-3366-95-8
bdbm50349330
STK590474
HMS2231G11
CCG-100896
CCG-39993
AKOS005512552
secnidazole [usan:inn:ban:dcf]
r3459k699k ,
solosec
unii-r3459k699k
nsc 759812
sym 1219
FT-0601624
NCGC00095158-05
HMS3369N08
secnidazole [usan]
.alpha.,2-dimethyl-5-nitroimidazole-1-ethanol
secnidazole [mart.]
secnidazole [mi]
1h-imidazole-1-ethanol, .alpha.,2-dimethyl-5-nitro-
secnidazole [who-dd]
secnidazole [inn]
secnidazole [orange book]
AB00456738-13
MLS006011434
NC00146
tox21_111457_1
NCGC00095158-04
KS-1191
CS-4641
SCHEMBL363924
alpha,2-dimethyl-5-nitro-1h-imidazole-1-ethanol
AKOS025149490
HY-B1118
1-(2-methyl-5-nitroimidazol-1-yl)-2-propanol
AB00456738_16
AB00456738_17
OPERA_ID_1811
mfcd00864656
SR-01000685111-7
SR-01000685111-6
sr-01000685111
SR-01000685111-4
CHEBI:94433
HMS3656G14
J-019291
SBI-0207037.P001
HMS3714I05
SW197526-3
1-(2-methyl-5-nitro-1h-imidazol-1-yl) propan-2- ol
DB12834
1-(2- hydroxypropyl)-2-methyl-5-nitroimidazole
Q4413249
sindose
secnil
S2537
secnidazole (flagentyl)
BCP12459
BRD-A70083328-001-12-8
SB19197
rp-14539;pm-185184
NCGC00095158-08
1h-imidazole-1-ethanol, a,2-dimethyl-5-nitro-
secnidazole 100 microg/ml in acetonitrile
EN300-1721671
Z1198155412
1-(2'-hydroxypropyl)-2-methyl-5-nitroimidazole
secnidazole (mart.)
secnidazolum (inn-latin)
1-(2-methyl-5-nitro-1h-imidazol-1-yl) propan-2 ol
1-(2 hydroxypropyl)-2-methyl-5-nitroimidazole
secnidazol (inn-spanish)
p01ab07
1h-imidazole-1-ethanol, alpha,2-dimethyl-5-nitro-

Research Excerpts

Overview

Secnidazole is an efficacious, low-cost medication used for the treatment of giardiosis in humans. It has the advantage of requiring only a single oral dose.

ExcerptReferenceRelevance
"Secnidazole is an efficacious, low-cost medication used for the treatment of giardiosis in humans and has the advantage of requiring only a single oral dose."( Successful use of secnidazole to manage a giardiosis outbreak in a shelter.
Cheung, W; Maher, S; Malik, R; Russo, C; Šlapeta, J, 2019
)
1.57
"Secnidazole is a next-generation 5-nitroimidazole approved for more than three decades in Europe, Asia, South America and Africa and recently in the USA as a single-dose (2 g) treatment of bacterial vaginosis (BV). "( Secnidazole: next-generation antimicrobial agent for bacterial vaginosis treatment.
Nyirjesy, P; Schwebke, JR, 2018
)
3.37
"Secnidazole is a long-lasting nitroimidazole antimicrobial agent that is used as racemic mixture in clinical settings. "( Enantioselective HPLC determination and pharmacokinetic study of secnidazole enantiomers in rats.
Chen, X; Chen, Y; Du, J; Liu, D; Zhang, Y; Zhong, D, 2014
)
2.08

Effects

ExcerptReferenceRelevance
"Secnidazole (SEC) has been suggested as an alternative agent against Trichomonas vaginalis to overcome the adverse effects, antimicrobial resistance problems and poor adherence to the currently available therapy. "( Thermosensitive hydrogels for vaginal delivery of secnidazole as an approach to overcome the systemic side-effects of oral preparations.
Argenta, DF; Bernardo, BDC; Caon, T; Chamorro, AF; Matos, PR, 2021
)
2.32

Toxicity

ExcerptReferenceRelevance
" We concluded that they are equally useful the metronidazol for 10 days, and the secnidazol for 3 or 7 days, without the presence of adverse effects."( [Comparative study for the evaluation of the efficacy and safety of metronidazole and secnidazole in the treatment of vaginal trichomoniasis].
Buitrón García Figueroa, R; Gonzalo Butrón López, F; Oropez Rechy, G; Romero-Cabello, R, 1997
)
0.52
" Adverse events considered by the investigator to be related to study drug occurred in only 20."( A phase-3, double-blind, placebo-controlled study of the effectiveness and safety of single oral doses of secnidazole 2 g for the treatment of women with bacterial vaginosis.
Koltun, W; Morgan, FG; Nyirjesy, P; Schwebke, JR, 2017
)
0.67
" The most frequently reported treatment-emergent adverse events with SYM-1219 were headache, dizziness, and nausea."( Thorough QT/QTc Evaluation of the Cardiac Safety of Secnidazole at Therapeutic and Supratherapeutic Doses in Healthy Individuals.
Adetoro, N; Darpo, B; Matthews, BG; Pentikis, HS; Xue, H, 2018
)
0.73
" Standard 5- to 7-day antimicrobial treatments for BV are associated with high rates of recurrence and adverse events."( Two Phase 1, Open-Label, Single-Dose, Randomized, Crossover Studies to Assess the Pharmacokinetics, Safety, and Tolerability of Orally Administered Granules of Secnidazole (2 g) in Healthy Female Volunteers Under Different Administration Conditions.
Adetoro, N; Pentikis, HS, 2018
)
0.68
" The overall number of treatment-emergent adverse events (TEAEs) was 95 (29."( A Phase 3, Multicenter, Prospective, Open-Label Study to Evaluate the Safety of a Single Dose of Secnidazole 2 g for the Treatment of Women and Postmenarchal Adolescent Girls with Bacterial Vaginosis.
Chavoustie, SE; Gersten, JK; Samuel, MJ; Schwebke, JR, 2018
)
0.7
" The extracted outcomes were the clinical cure and adverse effects."( Efficacy and safety of single dose of oral secnidazole 2 g in treatment of bacterial vaginosis: A systematic review and meta-analysis.
Abbas, AM; Badawy, MM; Elghazaly, SM; Hamam, KM; Samy, A; Yakoub Agha, NA, 2019
)
0.78

Pharmacokinetics

The pharmacokinetic parameters of two oral formulations of a 1 g dose of secnidazole (CAS 3366-95-8) were compared in an open-label, randomized, single oral dose, two-period cross-over design in 18 healthy volunteers under fasting conditions.

ExcerptReferenceRelevance
"The pharmacokinetic parameters of two oral formulations of a 1 g dose of secnidazole (CAS 3366-95-8, secnidazole tablet as reference and another capsule preparation as test) were compared in an open-label, randomized, single oral dose, two-period cross-over design in 18 healthy volunteers under fasting conditions."( Evaluation of the bioequivalence and pharmacokinetics of two formulations of secnidazole after single oral administration in healthy volunteers.
Chen, J; Duan, H; Feng, L; Hu, KL; Jiang, XG; Tao, WX; Zhu, DQ, 2007
)
0.8
" The method was successfully used to determine the pharmacokinetic properties of secnidazole enantiomers in rats after administration of the racemate and individual enantiomers."( Enantioselective HPLC determination and pharmacokinetic study of secnidazole enantiomers in rats.
Chen, X; Chen, Y; Du, J; Liu, D; Zhang, Y; Zhong, D, 2014
)
0.87
" In both studies median fasted time to maximum plasma concentration was 4 hours (6 hours fed in study 102), and mean half-life ranged from 17 to 19 hours."( Two Phase 1, Open-Label, Single-Dose, Randomized, Crossover Studies to Assess the Pharmacokinetics, Safety, and Tolerability of Orally Administered Granules of Secnidazole (2 g) in Healthy Female Volunteers Under Different Administration Conditions.
Adetoro, N; Pentikis, HS, 2018
)
0.68

Compound-Compound Interactions

ExcerptReferenceRelevance
"SUMMARY Eradikacion therapy at patients with chronic pancreatitis and combined with Helicobacter associated erosive gastropathy in a month after treatment appeared successful at 75% patients which accepted therapy of the first line--pantoprazol, amoksicillin, klaritromicin."( [Estimation of efficiency of anti-helicobacter therapy in patients with a chronic pancreatitis combined with an erosive gastropathy].
Kotsiubniak, LA; Koval', VIu; Moskal', OM, 2014
)
0.4

Bioavailability

ExcerptReferenceRelevance
"Coadministration of SYM-1219 and EE2/NET, either on the same day or 1 day apart, had no clinically relevant effects on the bioavailability of EE2 or NET."( Lack of a Pharmacokinetic Interaction Between SYM-1219 Granules Containing 2 Grams of Secnidazole and a Combined Oral Contraceptive in a Phase 1, Randomized, Open-Label Study in Healthy Female Volunteers.
Adetoro, N; Braun, CJ; Pentikis, HS, 2017
)
0.68
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Simple and accurate spectrophotometric and HPLC methods were developed for the determination of secnidazole in tablets dosage form. The developed method was successfully applied to the pharmacokinetic and bioequivalence studies following a single 500 mg oral dosage to 20 healthy volunteers.

ExcerptRelevanceReference
" in patients with intestinal amoebiasis or giardiasis, clinical or parasistological cure rates of 80 to 100% are achieved after treatment with a single dose of secnidazole 2g (30 mg/kg in children), similar to the response rates achieved with multiple dosage regimens of metronidazole or tinidazole."( Secnidazole. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic use in the management of protozoal infections and bacterial vaginosis.
Gillis, JC; Wiseman, LR, 1996
)
1.93
"Simple and accurate spectrophotometric and HPLC methods were developed for the determination of secnidazole in tablets dosage form."( Spectrophotometric and HPLC determination of secnidazole in pharmaceutical tablets.
Abdine, HH; El Wallily, AF; Razak, OA; Zamel, S, 2000
)
0.78
" The developed method was successfully applied to the pharmacokinetic and bioequivalence studies between test and reference secnidazole tablets following a single 500 mg oral dosage to 20 healthy volunteers of both genders."( Determination of secnidazole in human plasma by high-performance liquid chromatography with UV detection and its application to the bioequivalence studies.
Gu, Y; Li, X; Ren, H; Sun, J; Wang, G; Xie, H; Yan, B; Zheng, Y, 2007
)
0.89
"Gel dosage forms are successfully used as drug delivery systems considering their ability to prolong the drug release."( Formulation and in vitro evaluation of in situ gels containing secnidazole for vaginitis.
Gulzar A, M; Harish, NM; Narayana, RC; Prabhakara, P; Singh, AK; Subrahmanyam, EV, 2009
)
0.59
" Studies 102 and 103 each dosed 24 subjects (mean [standard deviation] ages, 36 [1."( Two Phase 1, Open-Label, Single-Dose, Randomized, Crossover Studies to Assess the Pharmacokinetics, Safety, and Tolerability of Orally Administered Granules of Secnidazole (2 g) in Healthy Female Volunteers Under Different Administration Conditions.
Adetoro, N; Pentikis, HS, 2018
)
0.68
" Currently recommended treatments require extended dosing and are thus associated with poor adherence."( An Integrated Efficacy and Safety Analysis of Single-Dose Secnidazole 2 g in the Treatment of Bacterial Vaginosis.
Adetoro, N; Levy, S; Pentikis, H; Tipping, D, 2020
)
0.8
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
epitopeThe biological role played by a material entity when bound by a receptor of the adaptive immune system. Specific site on an antigen to which an antibody binds.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
C-nitro compoundA nitro compound having the nitro group (-NO2) attached to a carbon atom.
imidazolesA five-membered organic heterocycle containing two nitrogen atoms at positions 1 and 3, or any of its derivatives; compounds containing an imidazole skeleton.
secondary alcoholA secondary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has two other carbon atoms attached to it.
imidazolesA five-membered organic heterocycle containing two nitrogen atoms at positions 1 and 3, or any of its derivatives; compounds containing an imidazole skeleton.
C-nitro compoundA nitro compound having the nitro group (-NO2) attached to a carbon atom.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (10)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RAR-related orphan receptor gammaMus musculus (house mouse)Potency0.15300.006038.004119,952.5996AID1159521; AID1159523
GLI family zinc finger 3Homo sapiens (human)Potency29.01450.000714.592883.7951AID1259369; AID1259392
EWS/FLI fusion proteinHomo sapiens (human)Potency32.64250.001310.157742.8575AID1259252; AID1259253; AID1259256
pregnane X nuclear receptorHomo sapiens (human)Potency31.62280.005428.02631,258.9301AID1346985
serine-protein kinase ATM isoform aHomo sapiens (human)Potency7.07950.707925.111941.2351AID485349
mitogen-activated protein kinase 1Homo sapiens (human)Potency5.01190.039816.784239.8107AID1454
gemininHomo sapiens (human)Potency7.35550.004611.374133.4983AID624296; AID624297
muscleblind-like protein 1 isoform 1Homo sapiens (human)Potency24.80330.00419.962528.1838AID2675
TAR DNA-binding protein 43Homo sapiens (human)Potency17.78281.778316.208135.4813AID652104
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
3-oxoacyl-[acyl-carrier-protein] synthase 3 Escherichia coliIC50 (µMol)28.50002.10004.20006.3000AID610072
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (18)

Processvia Protein(s)Taxonomy
negative regulation of protein phosphorylationTAR DNA-binding protein 43Homo sapiens (human)
mRNA processingTAR DNA-binding protein 43Homo sapiens (human)
RNA splicingTAR DNA-binding protein 43Homo sapiens (human)
negative regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
regulation of protein stabilityTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of insulin secretionTAR DNA-binding protein 43Homo sapiens (human)
response to endoplasmic reticulum stressTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of protein import into nucleusTAR DNA-binding protein 43Homo sapiens (human)
regulation of circadian rhythmTAR DNA-binding protein 43Homo sapiens (human)
regulation of apoptotic processTAR DNA-binding protein 43Homo sapiens (human)
negative regulation by host of viral transcriptionTAR DNA-binding protein 43Homo sapiens (human)
rhythmic processTAR DNA-binding protein 43Homo sapiens (human)
regulation of cell cycleTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA destabilizationTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationTAR DNA-binding protein 43Homo sapiens (human)
nuclear inner membrane organizationTAR DNA-binding protein 43Homo sapiens (human)
amyloid fibril formationTAR DNA-binding protein 43Homo sapiens (human)
regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (10)

Processvia Protein(s)Taxonomy
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
double-stranded DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
RNA bindingTAR DNA-binding protein 43Homo sapiens (human)
mRNA 3'-UTR bindingTAR DNA-binding protein 43Homo sapiens (human)
protein bindingTAR DNA-binding protein 43Homo sapiens (human)
lipid bindingTAR DNA-binding protein 43Homo sapiens (human)
identical protein bindingTAR DNA-binding protein 43Homo sapiens (human)
pre-mRNA intronic bindingTAR DNA-binding protein 43Homo sapiens (human)
molecular condensate scaffold activityTAR DNA-binding protein 43Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (9)

Processvia Protein(s)Taxonomy
intracellular non-membrane-bounded organelleTAR DNA-binding protein 43Homo sapiens (human)
nucleusTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
perichromatin fibrilsTAR DNA-binding protein 43Homo sapiens (human)
mitochondrionTAR DNA-binding protein 43Homo sapiens (human)
cytoplasmic stress granuleTAR DNA-binding protein 43Homo sapiens (human)
nuclear speckTAR DNA-binding protein 43Homo sapiens (human)
interchromatin granuleTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
chromatinTAR DNA-binding protein 43Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (86)

Assay IDTitleYearJournalArticle
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347084qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Confirmatory Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347088qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): Viability assay - Alamar blue signal for LCMV Confirmatory Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347087qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Confirmatory Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347081qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Confirmatory Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID416735Induction of mutagenicity in Salmonella Typhimurium YG1042 assessed as number of revertant per nmol after 48 hrs relative to metranidazole2009European journal of medicinal chemistry, Feb, Volume: 44, Issue:2
Lowering of 5-nitroimidazole's mutagenicity: towards optimal antiparasitic pharmacophore.
AID1456709In vivo antiparasitic activity against Giardia lamblia infected in human assessed as median efficacy at 30 mg/kg administered in children as single dose2017Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18
Nitroimidazoles: Molecular Fireworks That Combat a Broad Spectrum of Infectious Diseases.
AID1755883Selectivity index, ratio of CC50 for African green monkey Vero cells to IC50 for antigiardial activity against Trichomonas vaginalis GT32021European journal of medicinal chemistry, Jan-15, Volume: 210Metronidazole-conjugates: A comprehensive review of recent developments towards synthesis and medicinal perspective.
AID610073Toxicity in erythrocytes assessed as hemolytic activity2011Bioorganic & medicinal chemistry, Aug-01, Volume: 19, Issue:15
Synthesis, molecular modeling and biological evaluation of β-ketoacyl-acyl carrier protein synthase III (FabH) as novel antibacterial agents.
AID416729Cytotoxicity against human THP1 cells after 72 hrs by propidium iodide-based flow cytometry2009European journal of medicinal chemistry, Feb, Volume: 44, Issue:2
Lowering of 5-nitroimidazole's mutagenicity: towards optimal antiparasitic pharmacophore.
AID416736Ratio of number of revertant per nmol of drug for Salmonella Typhimurium YG1042 to number of revertant per nmol of drug for Salmonella Typhimurium TA1002009European journal of medicinal chemistry, Feb, Volume: 44, Issue:2
Lowering of 5-nitroimidazole's mutagenicity: towards optimal antiparasitic pharmacophore.
AID1456703In vivo antiparasitic activity against Giardia lamblia infected in human assessed as median efficacy at 2 g administered in adults as single dose2017Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18
Nitroimidazoles: Molecular Fireworks That Combat a Broad Spectrum of Infectious Diseases.
AID1755864Anti-trichomonas activity against Trichomonas vaginalis GT3 incubated for 48 hrs2021European journal of medicinal chemistry, Jan-15, Volume: 210Metronidazole-conjugates: A comprehensive review of recent developments towards synthesis and medicinal perspective.
AID416727Antitrichomonas activity against Trichomonas vaginalis TVR87 after 48 hrs by trypan blue staining2009European journal of medicinal chemistry, Feb, Volume: 44, Issue:2
Lowering of 5-nitroimidazole's mutagenicity: towards optimal antiparasitic pharmacophore.
AID1456701Antibacterial activity against Bacteroides fragilis ATCC 23745 after 24 hrs2017Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18
Nitroimidazoles: Molecular Fireworks That Combat a Broad Spectrum of Infectious Diseases.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID416734Induction of mutagenicity in Salmonella Typhimurium TA100 assessed as number of revertant per nmol after 48 hrs relative to metranidazole2009European journal of medicinal chemistry, Feb, Volume: 44, Issue:2
Lowering of 5-nitroimidazole's mutagenicity: towards optimal antiparasitic pharmacophore.
AID416730Induction of mutagenicity in Salmonella Typhimurium YG1042 assessed as number of revertant per ug after 48 hrs2009European journal of medicinal chemistry, Feb, Volume: 44, Issue:2
Lowering of 5-nitroimidazole's mutagenicity: towards optimal antiparasitic pharmacophore.
AID416732Induction of mutagenicity in Salmonella Typhimurium YG1042 assessed as number of revertant per nmol after 48 hrs2009European journal of medicinal chemistry, Feb, Volume: 44, Issue:2
Lowering of 5-nitroimidazole's mutagenicity: towards optimal antiparasitic pharmacophore.
AID416731Induction of mutagenicity in Salmonella Typhimurium TA100 assessed as number of revertant per ug after 48 hrs2009European journal of medicinal chemistry, Feb, Volume: 44, Issue:2
Lowering of 5-nitroimidazole's mutagenicity: towards optimal antiparasitic pharmacophore.
AID416733Induction of mutagenicity in Salmonella Typhimurium TA100 assessed as number of revertant per nmol after 48 hrs2009European journal of medicinal chemistry, Feb, Volume: 44, Issue:2
Lowering of 5-nitroimidazole's mutagenicity: towards optimal antiparasitic pharmacophore.
AID1755863Antigiardial activity against Giardia intestinalis MSS:0696:1 incubated for 48 hrs2021European journal of medicinal chemistry, Jan-15, Volume: 210Metronidazole-conjugates: A comprehensive review of recent developments towards synthesis and medicinal perspective.
AID1743083Antigiardial activity against Giardia intestinalis IMSS:0696:1 incubated for 48 hrs followed by wash out by hemocytometric counting method2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Anti-
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1755882Selectivity index, ratio of CC50 for African green monkey Vero cells to IC50 for antigiardial activity against Giardia intestinalis MSS:0696:12021European journal of medicinal chemistry, Jan-15, Volume: 210Metronidazole-conjugates: A comprehensive review of recent developments towards synthesis and medicinal perspective.
AID416728Specificity index, ratio of IC50 for human THP1 cells to IC50 for Trichomonas vaginalis TVR872009European journal of medicinal chemistry, Feb, Volume: 44, Issue:2
Lowering of 5-nitroimidazole's mutagenicity: towards optimal antiparasitic pharmacophore.
AID610072Inhibition of N-terminal His-tagged Escherichia coli FabH expressed in Escherichia coli BL21 (DE3) using [3H]acetyl-coA after 25 mins by liquid scintillation counting2011Bioorganic & medicinal chemistry, Aug-01, Volume: 19, Issue:15
Synthesis, molecular modeling and biological evaluation of β-ketoacyl-acyl carrier protein synthase III (FabH) as novel antibacterial agents.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (140)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (4.29)18.7374
1990's22 (15.71)18.2507
2000's23 (16.43)29.6817
2010's59 (42.14)24.3611
2020's30 (21.43)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 82.91

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index82.91 (24.57)
Research Supply Index5.26 (2.92)
Research Growth Index5.16 (4.65)
Search Engine Demand Index151.04 (26.88)
Search Engine Supply Index2.09 (0.95)

This Compound (82.91)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials40 (26.32%)5.53%
Reviews13 (8.55%)6.00%
Case Studies8 (5.26%)4.05%
Observational1 (0.66%)0.25%
Other90 (59.21%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (9)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Multi-Center, Open-Label Study to Evaluate the Safety of a Single Oral Dose of Solosec™ (Secnidazole) 2g Oral Granules for the Treatment of Adolescent Girls With Bacterial Vaginosis [NCT03937869]Phase 440 participants (Actual)Interventional2018-11-28Completed
Safety and Clinical and Microbiological Efficacy of the Combination of Fluconazole and Secnidazole for the Treatment of Symptomatic Vaginal Discharge. Bogotá D. C. Colombia. [NCT02111629]Phase 3118 participants (Actual)Interventional2012-05-31Completed
Studies of Acute and Memory Immune Responses to Orally Administered Vaccines in Developing Country Children and Factors That May Augment Such Responses [NCT01019083]Phase 1/Phase 21,016 participants (Anticipated)Interventional2008-02-29Completed
Suppressive Antibacterial Therapy With Once-Weekly Secnidazole Granules to Prevent Recurrent Bacterial Vaginosis; A Pilot Study [NCT05033743]Phase 2/Phase 320 participants (Actual)Interventional2021-07-09Completed
Effects of Anti-Giardia and Antihelmintic Treatment on Infant Nutritional and Biochemical Status and Intestinal Permeability in Rural Bangladesh [NCT00607074]410 participants (Actual)Interventional2003-06-30Completed
A Phase 2, Multi-center, Prospective, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effectiveness and Safety of SYM-1219 for the Treatment of Women With Bacterial Vaginosis [NCT02147899]Phase 2215 participants (Actual)Interventional2014-05-31Completed
Multi-center, Prospective, Open-Label Study to Evaluate the Safety of A Single Dose of SYM-1219, a Granule Formulation Containing 2 Grams of Secnidazole, for the Treatment of Women and Postmenarchal Adolescent Girls With Bacterial Vaginosis [NCT02452866]Phase 3325 participants (Actual)Interventional2015-06-30Completed
A Third Phase, Multicentre, Randomized as a Double Blind Study, Triple Placebo, Comparative of the Efficacy and Safety of an Association Secnidazol-Ciprofloxacin Compared With Amoxicillin-Clavulanic Acid for the Treatment of Uncomplicated Episode of Diver [NCT01733966]Phase 3100 participants (Actual)Interventional2010-05-31Terminated(stopped due to difficulties to recruit patients who suffer from this pathology)
Multi-center, Prospective, Randomized, Placebo-Controlled, Delayed Treatment, Double-Blind Study to Evaluate the Effectiveness and Safety of a Single Oral Dose of Solosec® for the Treatment of Trichomoniasis [NCT03935217]Phase 3147 participants (Actual)Interventional2019-04-23Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT02147899 (2) [back to overview]Cure of Bacterial Vaginosis
NCT02147899 (2) [back to overview]Number of Patients With Therapeutic Cure
NCT02452866 (1) [back to overview]Numbers of Participants With Treatment Emergent Adverse Events and Laboratory Abnormalities
NCT03935217 (1) [back to overview]Microbiological Cure at the TOC Visit

Cure of Bacterial Vaginosis

Number of subjects with therapeutic cure at Test of Cure (TOC)/End of Study (EOS) (clinical cure + normalization of Nugent score) (NCT02147899)
Timeframe: Study Days 21-30

InterventionParticipants (Count of Participants)
SYM-1219 Low Dose64
SYM-1219 High Dose62
Placebo62

[back to top]

Number of Patients With Therapeutic Cure

Clinical Cure and Normalization of the Nugent score. The Nugent score is based on a microscopic assessment of a Gram stain of the vaginal fluid. (NCT02147899)
Timeframe: Study Days 21-30

InterventionParticipants (Count of Participants)
SYM-1219 Low Dose14
SYM-1219 High Dose25
Placebo4

[back to top]

Numbers of Participants With Treatment Emergent Adverse Events and Laboratory Abnormalities

Safety evaluations will be based on the incidence, intensity, and type of AEs of subjects with clinical cure at TOC/EOS (clinical cure basd on amsel + normalization of Nugent score) (NCT02452866)
Timeframe: 30days

InterventionParticipants (Count of Participants)
Patients with 1 or more TEAEPateints with Laboratory Abnormality
SYM-1219952

[back to top]

Microbiological Cure at the TOC Visit

Vaginal Culture negative for T. vaginalis at TOC Visit (NCT03935217)
Timeframe: Study Day 6-12

InterventionParticipants (Count of Participants)
Solosec 2 Grams59
Placebo1

[back to top]